Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Liabilities and Shareholders Equity: 2023-2025

Historic Liabilities and Shareholders Equity for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $299.4 million.

  • Immunome's Liabilities and Shareholders Equity rose 16.54% to $299.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 15.39%. This contributed to the annual value of $240.2 million for FY2024, which is 61.73% up from last year.
  • As of Q3 2025, Immunome's Liabilities and Shareholders Equity stood at $299.4 million, which was up 1.04% from $296.3 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Liabilities and Shareholders Equity registered a high of $342.7 million during Q1 2025, and its lowest value of $41.4 million during Q2 2023.
  • Over the past 3 years, Immunome's median Liabilities and Shareholders Equity value was $256.9 million (recorded in 2024), while the average stood at $216.6 million.
  • Data for Immunome's Liabilities and Shareholders Equity shows a peak YoY surged of 614.89% (in 2024) over the last 5 years.
  • Immunome's Liabilities and Shareholders Equity (Quarterly) stood at $148.5 million in 2023, then spiked by 61.73% to $240.2 million in 2024, then grew by 16.54% to $299.4 million in 2025.
  • Its Liabilities and Shareholders Equity was $299.4 million in Q3 2025, compared to $296.3 million in Q2 2025 and $342.7 million in Q1 2025.